𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic–pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model

✍ Scribed by Takayuki Katsube; Yoshinori Yamano; Yoshitaka Yano


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
183 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to simulate in vivo bactericidal effects for three carbapenem antibiotics, doripenem (DRPM), meropenem (MEPM)/cilastatin (CS), and imipenem (IPM)/CS, against a Pseudomonas aeruginosa (P. aeruginosa) strain is proposed. The PD model we have already developed to explain in vitro time-kill profiles was modified to incorporate the growth rate, bactericidal activities, and PK profiles in murine lung infection models. Plasma concentration data and bacterial time-kill data for each antibiotic consist of six and eight time points, respectively, at one dose regimen (four or five mouse/point).

In vivo time-kill curves could be well simulated for each antibiotic by the PK/PD model. Simulated bacterial counts at 24 h and PK/PD indices derived from total drug concentrations (time above the minimum inhibitory concentration (MIC) (T > MIC), C max / MIC, and AUC/MIC) for various dose regimens were examined for MEPM/CS and IPM/ CS. Simulated bacterial counts correlated only with T > MIC (correlation coefficient: 0.951 for MEPM/CS, 0.982 for IPM/CS) and T > MIC values to achieve a bacteriostatic effect and a 2-log killing effect for both antibiotics were estimated to be approximately 15 and 20%, respectively, which are similar to previously reported results. These findings suggested that the proposed PK/PD model is a good tool for predicting in vivo bactericidal effects.


📜 SIMILAR VOLUMES


Pharmacokinetic–pharmacodynamic modeling
✍ Takayuki Katsube; Yoshitaka Yano; Yoshinori Yamano; Tadashi Munekage; Naomi Kuro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to explain the data from an in vitro dynamic model is proposed. Two carbapenem antibiotics, doripenem and meropenem, and three Pseudomonas aeruginosa strains were used as example drugs and strains. The PD model we originally developed to

Pharmacokinetic/pharmacodynamic modeling
✍ Katsube, Takayuki (author);Yano, Yoshitaka (author);Wajima, Toshihiro (author);Y 📂 Article 📅 2010 🏛 John Wiley and Sons Inc. 🌐 English ⚖ 170 KB

The aim of this study was to obtain information on effective dosage regimens of doripenem by a modeling and simulation approach based on pharmacokinetic (PK)/pharmacodynamic (PD) theory. The PK/PD model we have already developed was modified to explain in vitro bactericidal kinetics of doripenem for

Retracted: Convulsant activity and pharm
✍ Bikash Roy; Anirbandeep Bose; Uttam Bhaumik; Ayan Das; Nilendra Chatterjee; Anim 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

A pharmacokinetic-pharmacodynamic (PK-PD) modeling approach was used to investigate the epileptogenic activity of gemifloxacin as a representative antibiotic with concentration-dependent antimicrobial activity. Rats received an intravenous infusion of gemifloxacin at a rate of 4 mg kg of body weight

Application of pharmacokinetic–pharmacod
✍ Evelyn D. Lobo; David M. Soda; Joseph P. Balthasar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

We have shown that intravenous (i.v.) administration of anti-methotrexate (MTX) antibodies (AMAb) reduces the systemic exposure of intraperitoneal (i.p.) MTX therapy, and we have proposed that AMAb effects on MTX systemic exposure would allow a reduction in MTX-induced systemic toxicity (i.e., produ